JP2022546717A5 - - Google Patents

Info

Publication number
JP2022546717A5
JP2022546717A5 JP2022514513A JP2022514513A JP2022546717A5 JP 2022546717 A5 JP2022546717 A5 JP 2022546717A5 JP 2022514513 A JP2022514513 A JP 2022514513A JP 2022514513 A JP2022514513 A JP 2022514513A JP 2022546717 A5 JP2022546717 A5 JP 2022546717A5
Authority
JP
Japan
Prior art keywords
disease
cancer
deficiency
tautomer
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022514513A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546717A (ja
Filing date
Publication date
Priority claimed from GBGB1912674.7A external-priority patent/GB201912674D0/en
Application filed filed Critical
Publication of JP2022546717A publication Critical patent/JP2022546717A/ja
Publication of JP2022546717A5 publication Critical patent/JP2022546717A5/ja
Ceased legal-status Critical Current

Links

JP2022514513A 2019-09-04 2020-09-03 Usp30阻害剤としての活性を有する置換シアノピロリジン類 Ceased JP2022546717A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1912674.7A GB201912674D0 (en) 2019-09-04 2019-09-04 Novel compounds
GB1912674.7 2019-09-04
PCT/EP2020/074540 WO2021043870A1 (en) 2019-09-04 2020-09-03 Substituted cyanopyrrolidines with activity as usp30 inhibitors

Publications (2)

Publication Number Publication Date
JP2022546717A JP2022546717A (ja) 2022-11-07
JP2022546717A5 true JP2022546717A5 (https=) 2023-09-11

Family

ID=68207049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022514513A Ceased JP2022546717A (ja) 2019-09-04 2020-09-03 Usp30阻害剤としての活性を有する置換シアノピロリジン類

Country Status (14)

Country Link
US (1) US20220315572A1 (https=)
EP (1) EP4025573B9 (https=)
JP (1) JP2022546717A (https=)
KR (1) KR20220054867A (https=)
CN (1) CN114341133B (https=)
AU (1) AU2020340527A1 (https=)
BR (1) BR112022003527A2 (https=)
CA (1) CA3146040A1 (https=)
CO (1) CO2022003608A2 (https=)
GB (1) GB201912674D0 (https=)
IL (1) IL290929B2 (https=)
MX (1) MX2022002686A (https=)
WO (1) WO2021043870A1 (https=)
ZA (1) ZA202203775B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的ペプチダーゼ30(usp30)阻害剤として有用な縮合二環化合物
JP7530889B2 (ja) 2018-10-05 2024-08-08 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ30(usp30)阻害剤として作用する縮合ピロリン
JP2023520727A (ja) 2020-04-08 2023-05-18 ミッション セラピューティクス リミティド Usp30阻害剤として活性を有するn-シアノピロリジン
IL298526A (en) 2020-05-28 2023-01-01 Mission Therapeutics Ltd N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
US20230303547A1 (en) 2020-06-04 2023-09-28 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
DK4161929T3 (da) 2020-06-08 2025-08-18 Mission Therapeutics Ltd 1-(5-(2-cyanopyridin-4-yl)oxazol-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrol-5(1h)-carbonitril som usp30-hæmmer til anvendelse i behandling af mitokondriedysfunktion, cancer og fibrose
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
JP2024544660A (ja) 2021-12-01 2024-12-03 ミッション セラピューティクス リミティド Usp30阻害剤としての活性を有する置換n-シアノピロリジン
KR20240132148A (ko) * 2023-02-24 2024-09-03 연세대학교 산학협력단 인덴 유도체를 유효성분으로 포함하는 섬유화의 예방 또는 치료용 조성물
GB202408928D0 (en) 2024-06-21 2024-08-07 Mission Therapeutics Ltd Novel compounds
GB202411060D0 (en) 2024-07-29 2024-09-11 Mission Therapeutics Ltd Novel compounds

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
EP1272467A4 (en) 2000-04-06 2003-05-07 Merck Frosst Canada Inc Cathepsin cysteine protease inhibitors
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
SG174050A1 (en) 2006-04-13 2011-09-29 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
TWI433677B (zh) 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
US20090264431A1 (en) 2007-08-20 2009-10-22 Palovich Michael R Novel cathepsin c inhibitors and their use
WO2009129370A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
WO2009129365A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
WO2009129371A1 (en) 2008-04-18 2009-10-22 Glaxo Group Limited Cathepsin c inhibitors
US20120309820A1 (en) 2011-06-04 2012-12-06 Jb Therapeutics Inc. Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
EP2565186A1 (en) 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
RS58361B1 (sr) 2013-07-31 2019-03-29 Merck Patent Gmbh Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba
US9963444B2 (en) 2014-05-19 2018-05-08 Northeastern University N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof
US20170095457A1 (en) 2014-05-27 2017-04-06 David Lonergan Compositions and methods of delivery of deubiquitinase inhibitors
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
WO2016040508A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
CA2976741C (en) * 2015-03-30 2023-01-17 Mission Therapeutics Limited 1-cyano-pyrrolidine compounds as usp30 inhibitors
WO2017009650A1 (en) 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201522267D0 (en) * 2015-12-17 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201522768D0 (en) 2015-12-23 2016-02-03 Mission Therapeutics Ltd Novel compounds
GB201602854D0 (en) 2016-02-18 2016-04-06 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
GB201604638D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
CN108884068B (zh) 2016-03-24 2021-02-26 特殊治疗有限公司 作为dub抑制剂的1-氰基-吡咯烷衍生物
US11014912B2 (en) 2016-09-27 2021-05-25 Mission Therapeutics Limited Cyanopyrrolidine derivatives with activity as inhibitors of USP30
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
TWI771327B (zh) 2016-10-05 2022-07-21 英商使命醫療公司 新穎化合物
US10968172B2 (en) 2017-05-15 2021-04-06 Mitobridge, Inc. USP30 inhibitors
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
GB2563595B (en) 2017-06-19 2020-04-15 Edwards Ltd Twin-shaft pumps
AU2018346597B2 (en) 2017-10-06 2023-07-13 Forma Therapeutics, Inc. Inhibiting Ubiquitin Specific Peptidase 30
GB2571731A (en) 2018-03-06 2019-09-11 Mission Therapeutics Ltd Novel compounds and uses
JP7449242B2 (ja) 2018-05-17 2024-03-13 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的ペプチダーゼ30(usp30)阻害剤として有用な縮合二環化合物
US11572374B2 (en) 2018-08-14 2023-02-07 Amgen Inc. N-cyano-7-azanorbornane derivatives and uses thereof
JP7530889B2 (ja) 2018-10-05 2024-08-08 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ30(usp30)阻害剤として作用する縮合ピロリン
IL298526A (en) * 2020-05-28 2023-01-01 Mission Therapeutics Ltd N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction

Similar Documents

Publication Publication Date Title
JP2022546717A5 (https=)
JP2023527025A5 (https=)
JP2023520727A5 (https=)
JP2023528087A5 (https=)
JP2020521730A5 (https=)
JP2023529570A5 (https=)
JP2019504009A5 (https=)
JP2019501142A5 (https=)
HRP20250891T1 (hr) 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primjenu u liječenju mitohondrijske disfunkcije, raka i fibroze
JP2019533659A5 (https=)
AP813A (en) Urea derivatives as inhibitors of IMPDH enzyme.
JP2024537824A5 (https=)
JP2016512844A5 (https=)
EP2699557B1 (en) 3-(oxazol-2-yl-ethoxy)- and 3-(thiazol-2-yl-ethoxy)-benzamide derivatives as anti-bacterial agents
WO2010115836A4 (en) Substituted piperidines as ccr3 antagonists
JP2019513135A5 (https=)
JP2019508467A5 (https=)
JP2017527578A5 (https=)
JP2019503362A5 (https=)
JP2020524166A5 (https=)
JP2010533160A5 (https=)
JP2010502767A5 (https=)
JP2010504280A5 (https=)
JP2023504415A5 (https=)
RU2019111882A (ru) Антагонисты trpv4